The Iong-term aim of this research is to determine the clinical consequences of genetic variability within the human CYP2C9 gene among subjects of diverse ethnic origins, and to understand molecular mechanisms that underlie genetically-based alterations in the functional activity of the CYP2C9 enzyme. CYP2C9 is a major human liver form of P450 that metabolizes approximately 15% of all drugs that are cleared by phase I processes. It is well established that treating patients that possess the common CYP2C9*2 and CYP2C9*3 variants with low therapeutic index drugs, e.g. warfarin, has clinically important implications. These are adverse drug reactions (ADRs) due to over-medication that can result in significant, but potentially avoidable, patient health costs. Although a large body of information exists for certain CYP2C9 polymorphisms in Caucasian subjects, the full spectrum of genetic variation at the CYP2C9 locus, and attendant functional consequences, is poorly defined. Moreover, other important ethnic groups in the US, notably Hispanics, have been quite neglected in this research area, despite evidence for population-specific polymorphisms in the CYP2C9 gene. Therefore, we will;
Specific Aim 1 : Identify the spectrum of distal regulatory polymorphisms that exist at the CYP2C9 locus. SNP discovery will be performed in a panel of 90 DNA samples from the Polymorphism Discovery Resource. SNP validation and allele frequency determinations will then be carried out in White and Hispanic populations.
Specific Aim 2 : Determine the functional significance of new promoter and coding-region polymorphisms in CYP2C9. Mechanisms underlying changes in function will be probed with reporter constructs, deletion analysis, DNA/binding protein assays, recombinantly expressed proteins and stably-transfected cell lines.
Specific Aim 3 : Determine the impact of new CYP2C9 polymorphisms on anticoagulation-related outcomes in previously phenotyped Caucasian patients by resequencing across 60 kbp of the CYP2C9 gene from 185 pre-existing warfarin patient DNA samples.
Aims 1 and 2 will test the hypothesis that; novel, functionally important polymorphisms remain to be elucidated within the CYP2C9 locus, some of which will be population-selective.
Aim 3 will test the hypothesis that; promoter-region SNPs in the CYP2C9 gene are a determinant of warfarin dose. Successful completion of these studies will impact the ability of clinicians to predict the likelihood of adverse drug reactions to warfarin, and other drugs that are CYP2C9 substrates, arising in minority populations.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM068797-04
Application #
7216381
Study Section
Pharmacology A Study Section (PHRA)
Program Officer
Okita, Richard T
Project Start
2004-04-01
Project End
2009-07-31
Budget Start
2007-04-01
Budget End
2009-07-31
Support Year
4
Fiscal Year
2007
Total Cost
$327,421
Indirect Cost
Name
University of Washington
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Farley, Sherry M; Leonard, Scott W; Taylor, Alan W et al. (2013) ?-Hydroxylation of phylloquinone by CYP4F2 is not increased by ?-tocopherol. Mol Nutr Food Res 57:1785-93
Edson, Katheryne Z; Prasad, Bhagwat; Unadkat, Jashvant D et al. (2013) Cytochrome P450-dependent catabolism of vitamin K: ?-hydroxylation catalyzed by human CYP4F2 and CYP4F11. Biochemistry 52:8276-85
Danese, E; Montagnana, M; Johnson, J A et al. (2012) Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Clin Pharmacol Ther 92:746-56
International Warfarin Pharmacogenetics Consortium; Klein, T E; Altman, R B et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360:753-64
Choppin, A; Irwin, I; Lach, L et al. (2009) Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs. Br J Pharmacol 158:1536-47
McDonald, Matthew G; Rieder, Mark J; Nakano, Mariko et al. (2009) CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 75:1337-46
Cooper, Gregory M; Johnson, Julie A; Langaee, Taimour Y et al. (2008) A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112:1022-7
Kramer, Melissa A; Rettie, Allan E; Rieder, Mark J et al. (2008) Novel CYP2C9 promoter variants and assessment of their impact on gene expression. Mol Pharmacol 73:1751-60
Meckley, Lisa M; Wittkowsky, Ann K; Rieder, Mark J et al. (2008) An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 100:229-39
Au, Nicholas; Rettie, Allan E (2008) Pharmacogenomics of 4-hydroxycoumarin anticoagulants. Drug Metab Rev 40:355-75

Showing the most recent 10 out of 16 publications